Figure 1. PRISMA Flow Diagram for Systematic
Literature Review a Abbreviations: PRO, patient-reported outcome; SCT, stem cell transplantation a The systematic review covered four burden of illness topics: epidemiology burden, humanistic, economic burden, and economic models. Only the results of the economic burden review are presented in this poster. b The search strategy was conducted as part of a wider search including a search for epidemiological data; exclusion criteria related to country of study were used for studies that only reported epidemiological data. c These were abstracts presented in conference proceedings that were searched. Three conference abstracts [5] [6] [7] from the American Society of Hematology and the European Hematology Association conferences were included as part of the review of economic burden. The overall cost of BOR monotherapy in the USA and UK ($17,046, £9,708) was found to be potentially lower than LEN/Dex in second-line MM therapy ($101,053, £58,927 per treatment).
France:
Retrospective chart review to evaluate the direct costs associated with the therapeutic management of RRMM 8 Mean monthly total costs were largely driven by drug costs and hospital visits for drug administration.
Mean costs for LEN-based regimens were largely driven by anti-cancer therapy (91.2%; €5,728 PPPM) compared with 66% (€3,950 PPPM) of total costs for BOR-based regimens and 63% (€813 PPPM) for THAL-based regimens.
Switzerland:
Prospective single-arm phase I/II trial to compare the costs of mobilising cells with vinorelbine to those with the standard method using with cyclophosphamide in historical control patients with high-risk RRMM. 9 Using vinorelbine decreased costs by approximately €1,700 due to 2 days fewer for hospitalisation and mobilisation.
The number of days of G-CSF application was the biggest driver in the cost differences, as cyclophosphamide required 2 additional days compared with vinorelbine.
USA:
Cost-effectiveness analysis (with cost data from 3 published RCTs) to estimate the incremental cost-effectiveness of VMP vs. MPT and VMP vs. MPR-R for previously untreated transplant-ineligible MM patients. 10 Drug costs for the newer chemorapeutic regimens VMP, MPT, and MPR-R ($2,476 to $4,491 PPPM) are higher than those for the older melphalan and prednisone (MP, $2,165 PPMM), as are medical costs for evaluation and management, drug administration, hydration, laboratory tests, and prophylaxis.
Netherlands:
Retrospective chart review to explore the real-world healthcare costs associated with using novel therapies for RRMM in daily practice; 11 related to reference 5.
Expenditure on therapy and hospital admissions were the main drivers behind increased costs.
Drug costs accounted for 67% of mean monthly costs for LEN-based regimens, 49% for BOR-based regimens, 30% for THAL-based regimens, and 32% across all regimens.
Costs attributable to hospital visits (largely for haematology or surgical ward visits as opposed to ICU visits) and admissions were important cost drivers for BOR-based and THAL-based regimens but less so for LEN-based regimens.
USA:
Retrospective database study to evaluate the resource utilisation of patients with MM receiving growth factor therapy following failed attempts at stem cell mobilisation during autologous transplants 12 Chemotherapy-based remobilisation resulted in significantly more red blood cell transfusions, platelet transfusions, and parenteral antibacterial therapies than non-chemotherapy-based remobilisation attempts.
Sweden:
Retrospective chart review to evaluate the direct costs and hospital resource utilisation associated with treatment for MM 13 58% of total costs (€2,270 PPPM) were related to direct costs of MM; inpatient hospitalisations for MM treatmentrelated costs for all lines of treatment accounted for 35%; 2% of the total cost was attributable to chemotherapy; and 8% was attributable to all drugs. The remaining 42% of total costs were attributed to therapy-induced AE or comorbidity-related costs.
Netherlands:
Retrospective cost-analysis to investigate the medical costs associated with skeletal complications in patients with Stage III MM 14 During the first year of treatment, total drug costs and chemotherapy costs were lower among patients older than 60 years managed by chemotherapy alone than among younger patients who underwent SCT.
After the first year, mean annual per-patient drug costs were somewhat higher among those older than 60 years, but mean annual per-patient chemotherapy costs were comparable between the two groups.
USA:
Retrospective database study to evaluate the medical costs and resource utilisation associated with HSC remobilisation for patients with MM using a modified hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD) regimen 15 Optimisation of HSC mobilisation regimens to reduce failure rates would reduce the overall medical costs.
Treatment with G-CSF accounted for most of the median cost per patient for remobilisation with hyper-CVAD.
Duration of apharesis was a significant driver of remobilisation costs.
Italy:
Single-centre, retrospective, observational study to estimate the healthcare resource utilisation and costs associated with Stage II-III a MM management by age group in a haematology department 16 Drug costs were the largest individual component of total annual costs, particularly among patients older than 65 years (50.4%, €7,001 per year) compared to younger people (33.0%, €4,675 per year).
USA:
Retrospective database study to compare the total healthcare costs and healthcare resource utilisation associated with BOR, THAL, LEN, and other therapies in patients with relapsed or previously untreated MM 17 Total healthcare costs, as well as patient out-of-pocket costs, were higher with THAL/LEN treatment episodes than with BOR-containing regimens. Costs for management of patients with progressive disease were substantially higher than for managing those in treatment-free or maintenance therapy state.
Key drivers of increased costs among patients with progressive disease were inpatient care, chemotherapy, and intensive care.
Netherlands:
Retrospective chart review to explore the real-world healthcare costs associated with using novel therapies for treating RRMM in daily practice; 11 related to reference 5.
The costs of therapy and hospital admissions increased with the line of therapy.
Study Design, Objective and Location Conclusions Related to the Economic Burden of Complications

France:
Retrospective chart review to evaluate the direct costs associated with the therapeutic management of RRMM 8 AEs or MM-related complications accounted for 6% of the total costs.
Netherlands:
Retrospective cost-analysis to understand the medical costs associated with skeletal complications in patients with Stage III MM 14 SREs accounted for 17% of total costs for managing Stage III MM patients across community and hospital settings in this study.
Costs associated with SREs accounted for a lower share of total costs in patients aged under 60 years than among those aged above 60 years of age; this was partly because overall treatment costs were higher in the younger group since they received SCT therapy, a more costly intervention than is chemotherapy alone.
USA:
Retrospective database cost-analysis to quantify the prevalence and direct medical care costs of MM patients with MBD and the resulting cost impact on the USA oncology expenditure 18 The costs of managing MM were greatly increased by the development of MBD, with outpatient costs being the largest driver of the additional expenditure.
MBD also added to inpatient and pharmacy costs incurred by patients with MM.
Study Design, Objective and Location Conclusions Related to the Economic Burden of Treatment-related AEs
France:
USA:
Cost-effectiveness analysis (with cost data from 3 published RCTs) to estimate the incremental cost-effectiveness of VMP versus MPT and VMP versus MPR-R as therapy for previously untreated transplant-ineligible MM patients 10 Costs for management of treatment-related AEs were considerable, particularly among patients who received MPR-R or MPT.
Sweden:
Retrospective chart review to evaluate the direct costs and hospital resource utilisation associated with treatment for MM 13 Therapy-induced and comorbidity-related events constituted 42% of total costs (i.e., as much as the combined costs for autologous SCT and inpatient care).
UK:
Retrospective 
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RESULTS (CONT'D)
The primary drivers of MM management costs are medication, hospitalisations, and AEs, particularly neutropenia, followed by thrombocytopenia, anaemia, and infections. Other key cost drivers included progressive disease and bone or skeletal complications. This highlights the need for effective therapies for MM with improved tolerability profiles that delay progression across a broad range of patients with and without comorbidities.
To review published evidence on the resource use and costs associated with MM using systematic literature review (SLR) methodology
Key Findings
The Cost of Managing MM Increases as the Disease Progresses and Worsens
In one economic model reporting trial-derived cost inputs, costs perpatient-per-month (PPPM) for patients with progressive disease were $837 (2010 USA dollars [USD]), which was nearly 4-fold those in patients without progressive disease after initial treatment ($237).
10
Chemotherapeutic Regimens Appear to be Associated with a Significant Cost Burden
Among patients with relapsed MM (RMM) or relapsed and refractory MM (RRMM), drugs costs accounted for up to 66% (€2,069) of total costs in studies conducted in Europe and the United States (USA). 5, 8, 11, 17 -Hospitalisation, including that for drug administration, accounted for up to 35% (€2,778) of total costs. 5, 8, 11, 13, 17 Overall annual drug costs in an Italian study (2003) (2004) accounted for 40.1% of total direct costs incurred by patients with MM. 16 These higher costs may be due to the use of new chemotherapeutic agents. In contrast with the newer estimates of drug costs, an older retrospective chart review (1998) (1999) (2000) (2001) (2002) showed much lower costs for chemotherapeutic agents (e.g., €162 per year among patients with MM aged 60 years or older who had at least one skeletal-related event [SRE] and received chemotherapy only). 14 
Bone or Skeletal Complications are Associated with Increased Economic Burden
In a chart review of patients from 2 hospitals in the Netherlands, the total direct medical cost for treatment of SREs was €6,937 (currency year 2002) per patient, accounting for 17% of the total cost of MM treatment. 14 Hospitalisation was the main driver of the treatment costs for SREs, followed by radiotherapy.
A case-control study comparing patients with MM and MBD to matched MM controls without MBD found that this additional complication carried significant excess direct costs of $57,720 per patient (2004 USD). 18 
MM Treatment-related Adverse Events Contribute to Costs and Resource Use
The PPPM costs for management of treatment-related AEs varied from $2,165 to $4,491 (2010 USD) among patients receiving one of four initial chemotherapeutic regimens for MM (MP, VMP, MPT, or MPR-R).
In one study, neutropenia accounted for about two-thirds of all treatmentrelated AE costs for patients on MP ($1,431 of $2,165 PPPM) and VMP ($1,586 of $2,476 PPPM), and three-quarters for those on MPT ($2,621 of $3,522 PPPM) and MPR-R ($3,339 of $4,491 PPPM). The next most costly treatment-related AEs were thrombocytopenia, anaemia, and infections. 10 
In Patients with RMM/RRMM, Adverse Events and Complications or Comorbidities Continue to Account for Significant Costs Despite the Use of Newer Treatments
In a retrospective chart review study in Sweden (in which patients had first received chemotherapy in 2001), the proportion of overall costs attributable to treatment-induced AEs and comorbidities was around 44% (€1,197 out of €2,729; 2006 €) in second-line therapy and 22% (€571 out of €2,563). 13 In a more recent retrospective chart review in France (involving patients treated in 2004-2007, generally with now-current regimens), AEs and other complications accounted for up to 7% of total costs (€118-€285 out of €2,097-€4,182; 2007 € ) associated with secondor later-line therapy. 8 Figure 1 outlines the review's selection of studies (total of 13, in 14 publications), using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement guidelines.
Search Results
Multiple myeloma (MM) accounts for approximately 1% of all cancers and 13% of haematologic malignancies. [1] [2] [3] [4] The potential burden of this incurable condition includes disability, complications, treatment-related adverse events (AE), progressive and relapsing disease requiring multiple lines of therapy, comorbidities, and caregiving requirements.
The impact of the above disease-and treatment-related attributes with regards to resource use and costs has not previously been explored systematically in a literature review.
Our review identified the following evidence gaps:
Limited data on costs associated with AEs and comorbidities in MM No studies of the economic burden of non-skeletal complications of MM (e.g., haematological, neurological, or renal complications)
No relevant data on patient productivity and caregiver burden related to MM No studies of the economic burden of MM outside the USA and European Union
